Eloralintide research peptide for laboratory investigation of selective amylin-receptor signalling and metabolic pathways.
For laboratory research only. Not for human or veterinary use. This page is scientific background, not medical advice or a treatment claim.
Product overview
Product typeResearch peptide
Research focusAmylin-receptor and metabolic signalling
FormLyophilised material in a vial
Research context
Eloralintide (LY3841136) is an investigational, long-acting selective amylin-receptor agonist described in published phase 1 and phase 2 studies. Those trials used controlled clinical-study preparations and do not establish the identity, comparability or suitability of a separately supplied research vial. The Research tab distinguishes reported study findings from claims about this product.
See the Research tab for linked publications and their evidence limits.
Batch documentation
Review available lot-matched analytical documentation on our batch testing page. A publication or test from another lot does not authenticate this vial.
Supply and laboratory handling
- Confirm the selected option, vial label and lot documentation on receipt.
- Keep sealed and protected from light and moisture; follow validated laboratory storage procedures.
- Record handling and follow applicable laboratory safety protocols.
Frequently asked questions
What is eloralintide?
It is an investigational peptide agonist designed to study amylin-receptor pathways.
Are published trial results applicable to this vial?
Trial findings relate to the specific investigational material and protocol used in those studies. They do not authenticate or validate this lot.
Where can I review analytical information?
Check the batch testing page and confirm that the documentation matches the lot printed on the vial.
Information reviewed: 28 September 2026.
Batch-specific analytical documentation
Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.
- Result available: a published report is available for the marked variation.
- Test pending: a sample has been submitted, but no completed result is being claimed.
- No indicator: no product-specific result is currently displayed for that variation.
Check the identifiers
Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.
Browse published lab results →
Storage and stability
Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.
| Form |
Suggested storage |
Important note |
| Sealed lyophilised material |
Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. |
Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling. |
| Reconstituted solution |
Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. |
Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed. |
No universal shelf-life is claimed
Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.
Published research
Eloralintide (LY3841136) has been studied as an investigational selective amylin-receptor agonist. The clinical publications below relate to defined trial preparations and do not validate this separately supplied research vial.
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 2026. Randomised placebo-controlled multiple-ascending-dose study in 100 adults with obesity or overweight; assessed safety, pharmacokinetics and exploratory weight outcomes. View on PubMed ↗
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 2025. Trial in 263 adults examining weight and safety endpoints over 48 weeks. View on PubMed ↗
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Published discovery and early clinical investigation including a single-ascending-dose phase 1 trial. View on PubMed ↗
Research endpoints are not product claims. Trial outcomes are not claims for this vial. They neither authenticate this batch nor establish its clinical suitability. Eloralintide remains an investigational research compound in this context. Confirm any identity or purity claim against lot-matched analytical documentation. Research use only; not for human or veterinary use.
References reviewed 28 September 2026.
